艾曲泊帕在骨髓增生异常综合征PDX模型中的临床前评估
本研究利用已建立的MDS患者来源异种移植(PDX)模型,首次将其作为临床前平台评估艾曲泊帕的疗效与安全性。研究纳入来自9例MDS患者样本的49例异种移植,通过流式细胞术定量人血小板及连续全外显子测序重建克隆演化。结果显示艾曲泊帕有效刺激MDS PDX中的血小板生成,且未对患者克隆组成产生不良影响。
要点
- MDS PDX模型可用于临床前评估艾曲泊帕等候选药物。
- 艾曲泊帕在MDS PDX中有效刺激血小板生成。
- 艾曲泊帕未对患者克隆组成产生不良影响。
核心结论
- 艾曲泊帕在MDS PDX模型中有效刺激血小板生成,且未对患者克隆组成产生不良影响。
- MDS PDX模型是临床试验前测试MDS新治疗概念的有用工具。
研究设计与样本
- 临床前研究,纳入来自9例MDS患者样本的49例PDX异种移植。
- 通过流式细胞术定量人血小板,并通过连续全外显子测序重建克隆骨髓演化。
- 实验设置允许在患者个体水平进行载体对照和重复对照分析,区分药物特异性效应与自然疾病进展。
主要发现
- 艾曲泊帕有效刺激MDS PDX中的血小板生成。
- 艾曲泊帕未对患者的克隆组成产生不良影响。
临床怎么用
- MDS PDX模型可作为临床试验前评估新治疗概念的临床前平台。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preclinical research of myelodysplastic syndromes (MDSs) is hampered by a lack of feasible disease models. Previously, we have established a robust patient-derived xenograft (PDX) model for MDS. Here we demonstrate for the first time that this model is applicable as a preclinical platform to address pending clinical questions by interrogating the efficacy and safety of the thrombopoietin receptor agonist eltrombopag. Our preclinical study included n = 49 xenografts generated from n = 9 MDS patient samples. Substance efficacy was evidenced by FACS-based human platelet quantification and clonal bone marrow evolution was reconstructed by serial whole-exome sequencing of the PDX samples. In contrast to clinical trials in humans, this experimental setup allowed vehicle- and replicate-controlled analyses on a patient-individual level deciphering substance-specific effects from natural disease progression. We found that eltrombopag effectively stimulated thrombopoiesis in MDS PDX without adversely affecting the patients' clonal composition. In conclusion, our MDS PDX model is a useful tool for testing new therapeutic concepts in MDS preceding clinical trials.
引用
- Schmitt N, Jann JC, Altrock E, et al. Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes. Leukemia. 2021. PMID: 34172896. doi:10.1038/s41375-021-01327-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。